Helen Branswell, STAT’s infectious disease reporter, gives an urgent update on the ongoing H5N1 bird flu outbreak, highlighting a concerning rise in human cases and potential mutation risks. The discussion also covers key findings from a recent weight loss medication showdown between Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Additionally, there's a deep dive into the talent shortage in the radiopharmaceutical industry, detailing the struggle to attract skilled professionals and the impact on cancer treatment innovations.

Helen Branswell discusses the state of the pandemic and rollout of booster shots for Covid-19. They also talk about an IPO implosion, a debate at the FDA, and the ups and downs of a career in biotech.